{
    "id": 2955,
    "fullName": "YES1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "YES1 over exp indicates an over expression of the Yes1 protein. However, the mechanism causing the over expression has not been specified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7525,
        "geneSymbol": "YES1",
        "terms": [
            "YES1",
            "c-yes",
            "HsT441",
            "P61-YES",
            "Yes"
        ]
    },
    "variant": "over exp",
    "createDate": "01/19/2015",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1623,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "YES1 over expression has been reported in colorectal, head and neck, renal, lung, stomach and breast cancers. In a preclinical study, siRNA knockdown of Yes1 in basal-like breast cancer cells resulted in reduced proliferation demonstrating a potential for Yes1 as a therapeutic target (PMID: 21779430).",
            "molecularProfile": {
                "id": 2780,
                "profileName": "YES1 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1746,
                    "pubMedId": 21779430,
                    "title": "Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21779430"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10674,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to lapatinib (Tykerb) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10676,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to lapatinib (Tykerb) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5576,
                "therapyName": "Dasatinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10675,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, dasatinib (Sprycel) treatment of Her2 positive breast cancer cells with YES1 amplification and overexpression restored sensitivity to trastuzumab (Herceptin) (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 5575,
                "therapyName": "Dasatinib + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification and overexpression of Yes1 contributed to trastuzumab (Herceptin) resistance in Her2 positive breast cancer cells, in culture (PMID: 28158234).",
            "molecularProfile": {
                "id": 27723,
                "profileName": "YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8734,
                    "pubMedId": 28158234,
                    "title": "Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28158234"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10678,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Sprycel (dasatinib) to Tagrisso (osimertinib) therapy inhibited growth of a Tagrisso (osimertinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and EGFR T790M with YES1 amplification and over expression in culture, and reduced tumor growth in xenograft models (PMID: 28416483).",
            "molecularProfile": {
                "id": 27724,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp"
            },
            "therapy": {
                "id": 4946,
                "therapyName": "Dasatinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10677,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of YES1 in a lung cancer cell line with an EGFR exon 19 deletion and T790M promoted acquired resistance to Tagrisso (osimertinib) in culture (PMID: 28416483).",
            "molecularProfile": {
                "id": 27725,
                "profileName": "EGFR exon 19 del EGFR T790M YES1 over exp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 8735,
                    "pubMedId": 28416483,
                    "title": "SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28416483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2780,
            "profileName": "YES1 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 11307,
                    "name": "Dasatinib",
                    "profileName": "YES1 over exp"
                }
            ]
        },
        {
            "id": 27723,
            "profileName": "YES1 amp YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27724,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 amp YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27725,
            "profileName": "EGFR exon 19 del EGFR T790M YES1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}